CSIMarket
 
Lexicon Pharmaceuticals Inc   (LXRX)
Other Ticker:  
 
 
Price: $2.6000 $0.17 6.996%
Day's High: $2.62 Week Perf: -7.47 %
Day's Low: $ 2.44 30 Day Perf: -21.69 %
Volume (M): 7,483 52 Wk High: $ 3.79
Volume (M$): $ 19,455 52 Wk Avg: $1.93
Open: $2.45 52 Wk Low: $0.92



 Market Capitalization (Millions $) 637
 Shares Outstanding (Millions) 245
 Employees 219
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -158
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 2

Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that is focused on the discovery, development, and commercialization of innovative therapies for the treatment of various diseases. The company's mission is to improve patient lives by bringing breakthrough medicines to market.

The company was founded in 1995 and is headquartered in The Woodlands, Texas. It has a team of experienced professionals who have a track record of success in drug discovery and development, regulatory affairs, and commercialization.

Lexicon Pharmaceuticals has a diverse pipeline of drug candidates that are being developed for the treatment of various conditions such as diabetes, neuropathic pain, carcinoid syndrome, and irritable bowel syndrome. One of their most advanced drug candidates is sotagliflozin, which is a dual inhibitor of sodium-glucose cotransporter 1 and It is being developed as an adjunct to insulin therapy for type 1 diabetes and as a monotherapy for type 2 diabetes.

Another key drug candidate is telotristat etiprate, which is the first and only FDA-approved treatment for carcinoid syndrome diarrhea. The drug is also being developed for the treatment of refractory carcinoid syndrome and pulmonary arterial hypertension.

In addition to its robust pipeline of drug candidates, Lexicon Pharmaceuticals has strategic collaborations with pharmaceutical and biotech companies such as Sanofi, Ipsen, and Bristol-Myers Squibb. These collaborations provide additional resources and expertise to help the company advance its drug candidates and bring them to market.

Overall, Lexicon Pharmaceuticals is a well-established biopharmaceutical company with a strong commitment to developing innovative treatments for patients with unmet medical needs. Its strong pipeline and strategic collaborations position the company for continued growth and success in the future.


   Company Address: 2445 Technology Forest Blvd. The Woodlands 77381 TX
   Company Phone Number: 863-3000   Stock Exchange / Ticker: NASDAQ LXRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Sotagliflozin Shown to Enhance Glycemic Control in Type 1 Diabetes Patients with Chronic Kidney Disease

Published Tue, Mar 12 2024 12:00 PM UTC

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease Type 1 diabetes is a chronic condition characterized by the body's inability to produce sufficient insulin, leading to elevated blood glucose levels. Chronic kidney disease (CKD) is a common complicat...

Product Service News

Sotagliflozin Resubmission for Type 1 Diabetes: A Potential Breakthrough Therapy for Glycemic Control

Published Mon, Mar 11 2024 11:00 AM UTC

aims to provide its readers with insightful articles surrounding advancements in the pharmaceutical industry. In this article, we will analyze two related publications concerning the resubmission of Sotagliflozin, a potential adjunct therapy for type 1 diabetes, and its impact on pharmaceutical company Lexicon.1. Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Di...

Financing Agreement

Lexicon Pharmaceuticals Announces $250 Million Private Placement of Equity Securities

Published Mon, Mar 11 2024 11:05 AM UTC



Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has recently revealed that it has entered into a securities purchase agreement for a private investment in public equity financing. The company expects to amass approximately $250 million in gross proceeds through this financing round, which will strengthen its financial position. The placement will involve the sale of a...

Product Service News

Exploring Lexicon Pharmaceuticals' Promising Future in the Pharmaceutical Landscape: INPEFA Launch and Pipeline Update Steer Towards Accelerated Growth

Published Mon, Jan 8 2024 12:01 PM UTC

Amidst the 42nd Annual J.P. Morgan Healthcare Conference, Lexicon Pharmaceuticals made significant strides in reinforcing its position as an industry leader. With an exciting update on their business and pipeline, the company showcased its commitment towards revolutionizing the pharmaceutical landscape. Notably, Lexicon announced the INPEFA launch, which holds immense promis...

Clinical Study

LX9211: A Breathtaking Advance in Neuropathic Pain Management

Published Thu, Nov 30 2023 12:30 PM UTC



Lexicon Pharmaceuticals has recently announced the enrollment of the first patient in the Phase 2b PROGRESS study for LX9211?a promising AAK1 inhibitor?for the treatment of Diabetic Peripheral Neuropathic Pain (DPNP). This milestone signifies the initiation of the late-stage development program for LX9211, representing a crucial step towards addressing the high unm...






 

Lexicon Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com